Cart
This product is not clubbable with other items in cart. Please remove this or other items to proceed further.
Deleting

No Items In Cart
This product is not clubbable with other items in cart. Please remove this or other items to proceed further.
No Items In Cart
无与伦比的质量...源于设计
为了满足对预灌封注射器日益增长的市场需求,West NovaPure活塞采用完善的弹性体配方生产而成。 这种材料已经被证明具有从灌装到储存到病人或医护人员最终使用的最佳物理性质。 卓越的洁净度和FluroTec阻隔膜性能有助于确保优异的药物相容性和保护性。
NovaPure属性:
西氏已经完成研究,确保组件能够轻松地整合到客户的药品灌装-包装生产工艺中。从概念到市场,西氏都与客户并肩合作,使组件能满足多种包装需求。
小容量:
散装袋
传送接口袋:
NovaPure®, Westar® and FluroTec® are registered trademarks of West Pharmaceutical Services, Inc., in the United States and other jurisdictions.
FluroTec technology is licensed from Daikyo Seiko, Ltd.
One of the main risks associated with drug delivery via vial containment systems is particles that can result from fragmentation and coring of rubber stoppers subjected to needle or spike punctures. This risk can be mitigated by using prefilled syringe systems, whereby the drug dosage has been filled into the syringe by the drug manufacturer. The drug dosage is then administered by subcutaneous or intramuscular injection. A prefilled syringe system generates fewer particles during drug administration, as compared to a vial containment system. Furthermore, this form of drug delivery system ensures efficiency and greater convenience.
Mary Tan
Specialist, Scientific Affairs, Singapore
Biosimilar development and approvals have been accelerated over the last several years. The rapid uptake in this category is due in large part to clarity on regulatory pathways that demonstrate interchangeability with the reference product and key patent expiry over the next decade. By 2025 injectable biosimilars are projected to comprise almost 50% of the accessible biologics market1. West recently conducted a survey of biosimilar companies to better understand their top needs for packaging and support services during drug development.
Abbey Hisler
Director, Strategic Marketing, Biologics
In recent years, an increasing variety of biologic drugs have been developed including vaccines, recombinant proteins, gene and cell therapies. In China, this increased demand will be reflected in a significant growth in the size of the bio-pharmaceutical industry. As a result, the Chinese government is increasing its investment.
Lynn Yao
Manager, Scientific Affairs, China
One of the main risks associated with drug delivery via vial containment systems is particles that can result from fragmentation and coring of rubber stoppers subjected to needle or spike punctures. This risk can be mitigated by using prefilled syringe systems, whereby the drug dosage has been filled into the syringe by the drug manufacturer. The drug dosage is then administered by subcutaneous or intramuscular injection. A prefilled syringe system generates fewer particles during drug administration, as compared to a vial containment system. Furthermore, this form of drug delivery system ensures efficiency and greater convenience.
Mary Tan
Specialist, Scientific Affairs, Singapore
Biosimilar development and approvals have been accelerated over the last several years. The rapid uptake in this category is due in large part to clarity on regulatory pathways that demonstrate interchangeability with the reference product and key patent expiry over the next decade. By 2025 injectable biosimilars are projected to comprise almost 50% of the accessible biologics market1. West recently conducted a survey of biosimilar companies to better understand their top needs for packaging and support services during drug development.
Abbey Hisler
Director, Strategic Marketing, Biologics
In recent years, an increasing variety of biologic drugs have been developed including vaccines, recombinant proteins, gene and cell therapies. In China, this increased demand will be reflected in a significant growth in the size of the bio-pharmaceutical industry. As a result, the Chinese government is increasing its investment.
Lynn Yao
Manager, Scientific Affairs, China